Company news

Cabaletta Bio, Inc. news in 2023

Cabaletta Bio, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

November 27, 2023

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

November 8, 2023

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform

November 5, 2023

Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis

November 5, 2023

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

October 29, 2023

Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201

October 1, 2023

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

August 29, 2023

Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201

August 21, 2023

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

August 9, 2023

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

July 23, 2023

Cabaletta Bio to Present at the Jefferies Healthcare Conference

May 30, 2023

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

May 21, 2023

Cabaletta Bio Announces Proposed Public Offering of Common Stock

May 16, 2023

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

May 16, 2023

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

May 15, 2023

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

May 1, 2023

Cabaletta Bio Receives FDA Fast Track Designation for CABA-201

April 30, 2023

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

April 24, 2023

Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 12, 2023

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus

March 30, 2023

Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 15, 2023

Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference

February 27, 2023

Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 4, 2023

Decks in 2023